Interventional Neuroradiology, Department of Neurology, Beijing Tiantan Hospital, Beijing, China.
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Beijing, China.
Stroke Vasc Neurol. 2024 Apr 30;9(2):181-188. doi: 10.1136/svn-2023-002433.
Unsuccessful thrombectomy of acute large vessel occlusions (LVOs) has been associated with unfavourable outcomes. Multiple randomised controlled trials (RCTs) have reported a failure rate of 12%-41% for thrombectomy procedures. Various factors contribute to failed thrombectomy, including technical difficulties in accessing the occlusion, unsuccessful thrombus retrieval, thrombotic reocclusion and pre-existing intracranial atherosclerotic stenosis. Although some studies have explored balloon dilation or permanent stenting as rescue intracranial angioplasty for failed thrombectomy in individual cases, there is currently no evidence from RCTs on this specific topic.
To evaluate the potential superiority of bailout angioplasty over standard treatment in cases of unsuccessful recanalisation (eTICI 0 to 2a) or residual severe stenosis (>70%) after thrombectomy in acute LVO patients within 24 hours of stroke onset.
This study is a multicentre, prospective, randomised, controlled clinical trial designed by investigators. It compares bailout angioplasty with standard therapy and follows an open-label treatment approach while maintaining a blinded outcome assessment (PROBE design). Our objective is to allocate 348 patients in a 1:1 ratio to either receive bailout angioplasty as an intervention or standard therapy as a control, following unsuccessful thrombectomy.
The main measure of interest is the modified Rankin Scale (mRS) Score, which will be assessed in a blinded manner at 90 (±14) days following randomisation. The primary effect size will be determined using ordered logistic regression to calculate the common OR, representing the shift on the six-category mRS Scale at the 90-day mark. Additionally, the safety outcomes will be evaluated, including symptomatic intracranial haemorrhage within 18-36 hours, severe procedure-related complications and mortality within 90 (±14) days, among others.
The ANGEL-REBOOT study aims to generate substantial evidence regarding the efficacy and safety of bailout intracranial angioplasty as a treatment option for patients with LVO who have experienced unsuccessful thrombectomy.
NCT05122286.
急性大血管闭塞(LVOs)的血栓切除术不成功与不良预后相关。多项随机对照试验(RCTs)报告血栓切除术的失败率为 12%-41%。多种因素导致血栓切除术失败,包括进入闭塞部位的技术困难、血栓不能成功取出、血栓再闭塞和预先存在的颅内动脉粥样硬化狭窄。尽管一些研究探讨了球囊扩张或永久性支架置入作为急性 LVO 患者血栓切除术后失败的补救性颅内血管成形术,但目前 RCTs 尚无关于这一特定主题的证据。
评估在急性 LVO 患者发病 24 小时内,对于未能再通(eTICI 0-2a)或血栓切除术后仍存在严重狭窄(>70%)的患者,采用补救性血管成形术是否优于标准治疗。
这是一项由研究者设计的多中心、前瞻性、随机、对照临床试验。它比较了补救性血管成形术与标准治疗,采用开放标签治疗方法,同时保持盲法结局评估(PROBE 设计)。我们的目标是将 348 例患者按照 1:1 的比例随机分配,分别接受补救性血管成形术或标准治疗。
主要观察指标是改良 Rankin 量表(mRS)评分,在随机分组后 90(±14)天进行盲法评估。主要疗效指标将使用有序逻辑回归计算共同比值比(OR),代表 90 天 mRS 量表上的六类变化。此外,还将评估安全性结局,包括 18-36 小时内症状性颅内出血、90(±14)天内严重的与操作相关的并发症和死亡率等。
ANGEL-REBOOT 研究旨在为接受不成功的血栓切除术的 LVO 患者使用补救性颅内血管成形术作为治疗选择的疗效和安全性提供有力证据。
NCT05122286。